Halozyme Therapeutics, Inc. (HALO) has a MoatMap StockRank of 92/100 based on Quality (75/100), Value (32/100), and Momentum (73/100) factor scores. The current signal is STRONG BUY. Halozyme operates an incredibly high-margin, asset-light royalty model based on its ENHANZE drug delivery technology, which allows subcutaneous administration of major biologics. It acts as an indispensable gatekeeper for pharma innovation, enjoying massive switching costs and a long reinvestment runway with virtually no capital expenditure.
Halozyme Therapeutics, Inc. is a biotechnology company focused on its proprietary ENHANZE® drug delivery technology, utilizing recombinant human hyaluronidase enzyme (rHuPH20). This innovative platform facilitates subcutaneous administration of biologics, thereby improving patient convenience and reducing healthcare costs. Halozyme operates primarily through a high-margin licensing model, partnering with major pharmaceutical companies to enhance the delivery of their blockbuster therapeutics.
| Price | $71.63 |
| Market Cap | $8.1B |
| P/E (TTM) | 25.12 |
| P/E (Forward) | 7.24 |
| Price/Book | 38.64 |
| Return on Equity | 99.4% |
| Return on Invested Capital | 20.7% |
| Debt/Equity | 991.21 |
| Gross Margin | 76.7% |
| Operating Margin | 49.0% |
| Revenue Growth | 42.2% |
| Free Cash Flow | $228M |
Halozyme Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).